CLAIMS

We claim:

1. An isolated antisense OGT inhibitory polynucleotide, wherein the polynucleotide is 18-30 nucleotides in length and has a sequence that hybridizes to OGT mRNA.

2. The isolated polynucleotide of claim 1, having

a sequence set forth in SEQ ID NO: 3, or

a sequence complementary to an 18-30 nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 173.

3. The isolated polynucleotide of claim 1, wherein the polynucleotide hybridizes to OGT mRNA under conditions of medium to high stringency.

4. A pharmaceutical composition comprising

(i) an antisense OGT inhibitory polynucleotide, wherein the polynucleotide is 18-30 nucleotides in length and has a sequence that hybridizes to OGT mRNA; and

(ii) a pharmaceutically acceptable carrier.

5. The composition of claim 4, wherein the polynucleotide has

a sequence set forth in SEQ ID NO: 3, or

a sequence complementary to an 18-30 nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 173.

6. The composition of claim 4, wherein the polynucleotide hybridizes to OGT mRNA under conditions of medium to high stringency.

7. The polynucleotide or composition of any one of the prior claims, wherein the polynucleotide has a sequence complementary to an 18-30 nucleotide sequence set forth in the coding region of SEQ ID NO: 1 or SEQ ID NO: 173.

8. The polynucleotide or composition of any one of the prior claims, wherein the polynucleotide has a sequence complementary to an 18-30 nucleotide sequence set forth in the regulatory region of SEQ ID NO: 173.

9. The polynucleotide or composition of any one of the prior claims, wherein the polynucleotide has a sequence complementary to an 18-30 nucleotide sequence set forth in the intronic region of SEQ ID NO: 173.

10. The polynucleotide or composition of any one of the prior claims, wherein the polynucleotide comprises a sequence selected from any one of SEQ ID NOs: 4-168.

11. The polynucleotide or composition of any one of claims 1-9, wherein the polynucleotide comprises a sequence complementary to an 18-30 nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 173 or a sequence corresponding to an 18-30 contiguous nucleotide fragment of SEQ ID NO: 3, wherein the sequence comprises a sequence selected from any one of SEQ ID NOs: 4-168.

12. The polynucleotide or composition of any one of claims 1-9, wherein the sequence of the polynucleotide comprises a fragment of any one of SEQ ID NOs: 4-168 and further comprises 1-10 nucleotide residues, such that the sequence of the polynucleotide corresponds to an 18-30 contiguous nucleotide fragment of SEQ ID NO: 3, or an 18-30 nucleotide molecule that is complementary to an 18-30 nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 173.

13. The polynucleotide or composition of any one of the prior claims, wherein the polynucleotide is an oligodeoxynucleotide.

14. The composition of any one of claims 4-13, wherein the pharmaceutically-acceptable carrier is a gel.

15. The composition of any one of claims 4-13, wherein the pharmaceutically-acceptable carrier comprises an alcohol.

16. The composition of any one of claims 4-13, wherein the pharmaceutically-acceptable carrier comprises a polyoxyethylene-polyoxypropylene copolymer.

17. The composition of any one of claims 4-13, wherein the pharmaceutically-acceptable carrier comprises Pluronic® F-127.

18. The composition of any one of claims 4-13, wherein the pharmaceutically-acceptable carrier comprises an alginate or hydrogel.

19. The composition of any one of claims 4-13, wherein the pharmaceutically-acceptable carrier comprises a cellulose-based carrier.

20. The composition of any one of claims 4-13, wherein the cellulose-based carrier is selected from the group consisting of hydroxymethyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose, and mixtures thereof.

21. The composition of any one of claims 4-20, wherein the composition is formulated for topical application

22. The composition of any one of claims 4-20, wherein the composition is formulated for local injection

23. The composition of any one of claims 4-20, wherein the composition is formulated in a wound dressing.

24. The composition of any one of claims 4-20, wherein the composition is formulated in a colloidal gel dressing.

25. The composition of any one of claims 4-20, wherein the composition is formulated for

sustained release.

26. The composition of any one of claims 4-20, wherein the composition is formulated for slow release, extended release, or controlled release.

27. The composition of any one of claims 4-20, wherein the composition is a liquid, cream, ointment, emulsion, lotion, spray, salve, foam, or paint.

28. The polynucleotide or composition of any one of the prior claims, wherein the polynucleotide or composition is for treatment of a subject having a wound.

29. The polynucleotide or composition of any one of the prior claims, wherein the wound is not healing at an expected rate.

30. The polynucleotide or composition of any one of the prior claims, wherein the wound is delayed, difficult to heal, or chronic.

31. The polynucleotide or composition of any one of the prior claims, wherein the wound is characterized at least in part by increased expression of OGT.

32. The polynucleotide or composition of any one of the prior claims, wherein the subject is diabetic.

33. The polynucleotide or composition of any one of the prior claims, wherein the subject has type 1 diabetes mellitus.

34. The polynucleotide or composition of any one of the prior claims, wherein the subject has type 2 diabetes mellitus.

35. The polynucleotide or composition of any one of the prior claims, wherein the subject has higher than normal blood glucose levels.

36. The polynucleotide or composition of any one of the prior claims, wherein the subject has insulin-resistant receptors.

37. The polynucleotide or composition of any one of the prior claims, wherein the subject is not diabetic.

38. The composition of any one of claims 4-37, and further comprising a second wound healing agent

39. The composition of any one of claims 4-37, and further comprising a second anti-OGT agent.

40. Use of an anti-OGT agent in the manufacture of a medicament for inhibiting OGT in a cell, comprising administering an anti-OGT agent to the cell, wherein the anti-OGT agent is chosen from:

(i) an antisense OGT inhibitory polynucleotide, wherein the polynucleotide is 18-30 nucleotides in length and has a sequence that hybridizes to OGT mRNA;

(ii) a double stranded RNA molecule that inhibits expression of OGT; and

(iii) a short hairpin RNA molecule that inhibits expression of OGT.

41. Use of an anti-OGT agent in the manufacture of a medicament for treating a subject having a wound, wherein the anti-OGT agent is chosen from

(i) an antisense OGT inhibitory polynucleotide, wherein the polynucleotide is 18-30 nucleotides in length and has a sequence that hybridizes to OGT mRNA;

(ii) a double stranded RNA molecule that inhibits expression of OGT; and

(iii) a short hairpin RNA molecule that inhibits expression of OGT.

42. The use of claim 40 or 41, wherein the polynucleotide hybridizes to OGT mRNA under conditions of medium to high stringency.

43. The use of claim 40 or 41, wherein the polynucleotide has

a sequence set forth in SEQ ID NO: 3 [the sequence of said 18-30 nucleotides corresponds to an 18-30 contiguous nucleotide fragment of SEQ ID NO: 3], or

a sequence complementary to an 18-30 nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 173.

44. The use of claim 40 or 41, wherein the polynucleotide is an antisense OGT polynucleotide

45. The use of claim 40 or 41, wherein the polynucleotide is an oligodeoxynucleotide.

46. The use of claim 40 or 41, wherein the antisense OGT polynucleotide comprises a sequence selected from any one of SEQ ID NOs: 4-168.

47. The use of claim 40 or 41, wherein the polynucleotide has a sequence complementary to an 18-30 nucleotide sequence set forth in the coding region of SEQ ID NO: 1 or SEQ ID NO: 173.

48. The use of claim 40 or 41, wherein the polynucleotide has a sequence complementary to an 18-30 nucleotide sequence set forth in the regulatory region of SEQ ID NO: 173.

49. The use of claim 40 or 41, wherein the polynucleotide has a sequence complementary to an 18-30 nucleotide sequence set forth in the intronic region of SEQ ID NO: 173.

50. The use of claim 40 or 41, wherein the polynucleotide comprises a sequence complementary to an 18-30 nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 173 or a sequence corresponding to an 18-30 contiguous nucleotide fragment of SEQ ID NO: 3, wherein the sequence comprises a sequence selected from any one of SEQ ID NOs: 4-168.

51. The use of claim 40 or 41, wherein the sequence of the polynucleotide comprises a fragment of any one of SEQ ID NOs: 4-168 and further comprises 1-10 nucleotide residues, such that the sequence of the polynucleotide corresponds to an 18-30 contiguous nucleotide fragment of SEQ ID NO: 3, or an 18-30 nucleotide molecule that is complementary to an 18-30 nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 173.

52. The use of claim 40 or 41, wherein the isolated double-stranded RNA molecule includes a first strand comprising a sequence selected from SEQ ID NOS: 169-171, and including about 11 to 27 nucleotides.

53. The use of claim 40 or 41, wherein the small hairpin RNA comprises the sequence of SEQ ID NO: 172.

54. The use of any one of claims 40-53, wherein the anti-OGT agent is provided in a pharmaceutical composition.

55. The use of claim 54, wherein the pharmaceutical composition further comprises a pharmaceutically-acceptable carrier.

56. The use of claim 55, wherein the pharmaceutically-acceptable carrier is a gel.

57. The use of claim 55, wherein the pharmaceutically-acceptable carrier comprises an alcohol.

58. The use of claim 55, wherein the pharmaceutically-acceptable carrier comprises a polyoxyethylene-polyoxypropylene copolymer.

59. The use of claim 55, wherein the pharmaceutically-acceptable carrier comprises Pluronic® F-127.

60. The use of claim 55, wherein the pharmaceutically-acceptable carrier comprises an alginate or hydrogel.

61. The use of claim 55, wherein the pharmaceutically-acceptable carrier comprises a cellulose-based carrier.

62. The use of claim 61, wherein the cellulose-based carrier is selected from the group consisting of hydroxymethyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose, and mixtures thereof.

63. The use of any one of claims 54-62, wherein the composition is formulated for topical application.

64. The use of any one of claims 54-62, wherein the composition is formulated for local injection.

65. The use of any one of claims 54-62, wherein the composition is formulated in a wound dressing.

66. The use of any one of claims 54-62, wherein the composition is formulated in a colloidal gel dressing.

67. The use of any one of claims 54-62, wherein the composition is formulated for sustained release.

68. The use of any one of claims 54-62, wherein the composition is formulated for slow release, extended release, or controlled release.

69. The use of any one of claims 54-62, wherein the composition is a liquid, cream, ointment, emulsion, lotion, spray, salve, foam, or paint.

70. The use of any one of claims 44 and 46-53, wherein the anti-OGT agent is administered

topically.

71. The use of any one of claims 44 and 46-53, wherein the anti-OGT agent is administered by local injection.

72. The use of any one of claims 44-71, wherein the composition or agent is for treatment of a subject having a wound.

73. The use of claim 72, wherein the wound is not healing at an expected rate.

74. The use of claim 72, wherein the wound is delayed, difficult to heal, or chronic.

75. The use of claim 72, wherein the wound is characterized at least in part by increased expression of OGT.

76. The use of any one of claims 44 and 46-53, wherein the cell includes insulin-resistant receptors.

77. The use of claim 76, wherein the cell is in a subject.

78. The use of any one of claims 45-75 and 77, wherein the subject is not a diabetic

79. The use of any one of claims 45-75 and 77, wherein the subject is diabetic.

80. The use of claim 79, wherein the subject has type 1 diabetes mellitus.

81. The use of claim 79, wherein the subject has type 2 diabetes mellitus.

82. The use of any one of claims 45-75 and 77, wherein the subject has higher than normal blood glucose levels.

83. The use of any one of claims 45-75 and 77, the subject has insulin-resistant receptors.

84. The use of any one of claims 45-83, further comprising the step of administering a second wound healing agent.

85. The use of any one of claims 45-83, further comprising the step of administering a second anti-OGT agent.

CLAIMS

We claim:

1. An isolated antisense OGT inhibitory polynucleotide, wherein the polynucleotide is 18-30 nucleotides in length and has a sequence that hybridizes to OGT mRNA.

2. The isolated polynucleotide of claim 1, having

a sequence set forth in SEQ ID NO: 3, or

a sequence complementary to an 18-30 nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 173.

3. The isolated polynucleotide of claim 1, wherein the polynucleotide hybridizes to OGT mRNA under conditions of medium to high stringency.

4. A pharmaceutical composition comprising

(i) an antisense OGT inhibitory polynucleotide, wherein the polynucleotide is 18-30 nucleotides in length and has a sequence that hybridizes to OGT mRNA; and

(ii) a pharmaceutically acceptable carrier.

5. The composition of claim 4, wherein the polynucleotide has

a sequence set forth in SEQ ID NO: 3, or

a sequence complementary to an 18-30 nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 173.

6. The composition of claim 4, wherein the polynucleotide hybridizes to OGT mRNA under conditions of medium to high stringency.

7. The polynucleotide or composition of any one of the prior claims, wherein the polynucleotide has a sequence complementary to an 18-30 nucleotide sequence set forth in the coding region of SEQ ID NO: 1 or SEQ ID NO: 173.

8. The polynucleotide or composition of any one of the prior claims, wherein the polynucleotide has a sequence complementary to an 18-30 nucleotide sequence set forth in the regulatory region of SEQ ID NO: 173.

9. The polynucleotide or composition of any one of the prior claims, wherein the polynucleotide has a sequence complementary to an 18-30 nucleotide sequence set forth in the intronic region of SEQ ID NO: 173.

10. The polynucleotide or composition of any one of the prior claims, wherein the polynucleotide comprises a sequence selected from any one of SEQ ID NOs: 4-168.

11. The polynucleotide or composition of any one of claims 1-9, wherein the polynucleotide comprises a sequence complementary to an 18-30 nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 173 or a sequence corresponding to an 18-30 contiguous nucleotide fragment of SEQ ID NO: 3, wherein the sequence comprises a sequence selected from any one of SEQ ID NOs: 4-168.

12. The polynucleotide or composition of any one of claims 1-9, wherein the sequence of the polynucleotide comprises a fragment of any one of SEQ ID NOs: 4-168 and further comprises 1-10 nucleotide residues, such that the sequence of the polynucleotide corresponds to an 18-30 contiguous nucleotide fragment of SEQ ID NO: 3, or an 18-30 nucleotide molecule that is complementary to an 18-30 nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 173.

13. The polynucleotide or composition of any one of the prior claims, wherein the polynucleotide is an oligodeoxynucleotide.

14. The composition of any one of claims 4-13, wherein the pharmaceutically-acceptable carrier is a gel.

15. The composition of any one of claims 4-13, wherein the pharmaceutically-acceptable carrier comprises an alcohol.

16. The composition of any one of claims 4-13, wherein the pharmaceutically-acceptable carrier comprises a polyoxyethylene-polyoxypropylene copolymer.

17. The composition of any one of claims 4-13, wherein the pharmaceutically-acceptable carrier comprises Pluronic® F-127.

18. The composition of any one of claims 4-13, wherein the pharmaceutically-acceptable carrier comprises an alginate or hydrogel.

19. The composition of any one of claims 4-13, wherein the pharmaceutically-acceptable carrier comprises a cellulose-based carrier.

20. The composition of any one of claims 4-13, wherein the cellulose-based carrier is selected from the group consisting of hydroxymethyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose, and mixtures thereof.

21. The composition of any one of claims 4-20, wherein the composition is formulated for topical application

22. The composition of any one of claims 4-20, wherein the composition is formulated for local injection

23. The composition of any one of claims 4-20, wherein the composition is formulated in a wound dressing.

24. The composition of any one of claims 4-20, wherein the composition is formulated in a colloidal gel dressing.

25. The composition of any one of claims 4-20, wherein the composition is formulated for

sustained release.

26. The composition of any one of claims 4-20, wherein the composition is formulated for slow release, extended release, or controlled release.

27. The composition of any one of claims 4-20, wherein the composition is a liquid, cream, ointment, emulsion, lotion, spray, salve, foam, or paint.

28. The polynucleotide or composition of any one of the prior claims, wherein the polynucleotide or composition is for treatment of a subject having a wound.

29. The polynucleotide or composition of any one of the prior claims, wherein the wound is not healing at an expected rate.

30. The polynucleotide or composition of any one of the prior claims, wherein the wound is delayed, difficult to heal, or chronic.

31. The polynucleotide or composition of any one of the prior claims, wherein the wound is characterized at least in part by increased expression of OGT.

32. The polynucleotide or composition of any one of the prior claims, wherein the subject is diabetic.

33. The polynucleotide or composition of any one of the prior claims, wherein the subject has type 1 diabetes mellitus.

34. The polynucleotide or composition of any one of the prior claims, wherein the subject has type 2 diabetes mellitus.

35. The polynucleotide or composition of any one of the prior claims, wherein the subject has higher than normal blood glucose levels.

36. The polynucleotide or composition of any one of the prior claims, wherein the subject has insulin-resistant receptors.

37. The polynucleotide or composition of any one of the prior claims, wherein the subject is not diabetic.

38. The composition of any one of claims 4-37, and further comprising a second wound healing agent

39. The composition of any one of claims 4-37, and further comprising a second anti-OGT agent.

40. Use of an anti-OGT agent in the manufacture of a medicament for ~~A method of~~ inhibiting OGT in a cell, comprising administering an anti-OGT agent to the cell, wherein the anti-OGT agent is chosen from:

(i) an antisense OGT inhibitory polynucleotide, wherein the polynucleotide is 18-30 nucleotides in length and has a sequence that hybridizes to OGT mRNA;

(ii) a double stranded RNA molecule that inhibits expression of OGT; and

(iii) a short hairpin RNA molecule that inhibits expression of OGT.

41. ~~A method of treating a subject having a wound, comprising administering~~Use of an anti-OGT agent in the manufacture of a medicament for treating a subject having a wound~~to the subject~~, wherein the anti-OGT agent is chosen from

(i) an antisense OGT inhibitory polynucleotide, wherein the polynucleotide is 18-30 nucleotides in length and has a sequence that hybridizes to OGT mRNA;

(ii) a double stranded RNA molecule that inhibits expression of OGT; and

(iii) a short hairpin RNA molecule that inhibits expression of OGT.

42. The ~~method~~ use of claim 40 or 41, wherein the polynucleotide hybridizes to OGT mRNA under conditions of medium to high stringency.

43. The ~~method~~ use of claim 40 or 41, wherein the polynucleotide has

a sequence set forth in SEQ ID NO: 3 [the sequence of said 18-30 nucleotides corresponds to an 18-30 contiguous nucleotide fragment of SEQ ID NO: 3], or

a sequence complementary to an 18-30 nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 173.

44. The ~~method~~ use of claim 40 or 41, wherein the polynucleotide is an antisense OGT polynucleotide

45. The ~~method~~ use of claim 40 or 41, wherein the polynucleotide is an oligodeoxynucleotide.

46. The ~~method~~ use of claim 40 or 41, wherein the antisense OGT polynucleotide comprises a sequence selected from any one of SEQ ID NOs: 4-168.

47. The ~~method~~ use of claim 40 or 41, wherein the polynucleotide has a sequence complementary to an 18-30 nucleotide sequence set forth in the coding region of SEQ ID NO: 1 or SEQ ID NO: 173.

48. The ~~method~~ use of claim 40 or 41, wherein the polynucleotide has a sequence complementary to an 18-30 nucleotide sequence set forth in the regulatory region of SEQ ID NO: 173.

49. The ~~method~~ use of claim 40 or 41, wherein the polynucleotide has a sequence complementary to an 18-30 nucleotide sequence set forth in the intronic region of SEQ ID NO: 173.

50. The ~~method~~ use of claim 40 or 41, wherein the polynucleotide comprises a sequence

complementary to an 18-30 nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 173 or a sequence corresponding to an 18-30 contiguous nucleotide fragment of SEQ ID NO: 3, wherein the sequence comprises a sequence selected from any one of SEQ ID NOs: 4-168.

51. The ~~method~~ use of claim 40 or 41, wherein the sequence of the polynucleotide comprises a fragment of any one of SEQ ID NOs: 4-168 and further comprises 1-10 nucleotide residues, such that the sequence of the polynucleotide corresponds to an 18-30 contiguous nucleotide fragment of SEQ ID NO: 3, or an 18-30 nucleotide molecule that is complementary to an 18-30 nucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 173.

52. The ~~method~~ use of claim 40 or 41, wherein the isolated double-stranded RNA molecule includes a first strand comprising a sequence selected from SEQ ID NOS: 169-171, and including about 11 to 27 nucleotides.

53. The ~~method~~ use of claim 40 or 41, wherein the small hairpin RNA comprises the sequence of SEQ ID NO: 172.

54. The ~~method~~ use of any one of claims ~~38~~40-53, wherein the anti-OGT agent is provided in a pharmaceutical composition.

55. The ~~method~~ use of claim 54, wherein the pharmaceutical composition further comprises a pharmaceutically-acceptable carrier.

56. The ~~method~~ use of claim 55, wherein the pharmaceutically-acceptable carrier is a gel.

57. The ~~method~~ use of claim 55, wherein the pharmaceutically-acceptable carrier comprises an alcohol.

58. The ~~method~~ use of claim 55, wherein the pharmaceutically-acceptable carrier comprises a polyoxyethylene-polyoxypropylene copolymer.

59. The ~~method~~ use of claim 55, wherein the pharmaceutically-acceptable carrier comprises Pluronic® F-127.

60. The ~~method~~ use of claim 55, wherein the pharmaceutically-acceptable carrier comprises an alginate or hydrogel.

61. The ~~method~~ use of claim 55, wherein the pharmaceutically-acceptable carrier comprises a cellulose-based carrier.

62. The ~~method~~ use of claim 61, wherein the cellulose-based carrier is selected from the group consisting of hydroxymethyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxypropylmethyl cellulose, and mixtures thereof.

63. The ~~method~~ use of any one of claims 54-62, wherein the composition is formulated for topical application.

64. The ~~method~~ use of any one of claims 54-62, wherein the composition is formulated for local injection.

65. The ~~method~~use of any one of claims 54-62, wherein the composition is formulated in a wound dressing.

66. The ~~method~~use of any one of claims 54-62, wherein the composition is formulated in a colloidal gel dressing.

67. The ~~method~~use of any one of claims 54-62, wherein the composition is formulated for sustained release.

68. The ~~method~~use of any one of claims 54-62, wherein the composition is formulated for slow release, extended release, or controlled release.

69. The ~~method~~use of any one of claims 54-62, wherein the composition is a liquid, cream, ointment, emulsion, lotion, spray, salve, foam, or paint.

70. The ~~method~~use of any one of claims 44 and 46-53, wherein the anti-OGT agent is administered topically.

71. The ~~method~~use of any one of claims 44 and 46-53, wherein the anti-OGT agent is administered by local injection.

72. The ~~method~~use of any one of claims 44-71, wherein the composition or agent is for treatment of a subject having a wound.

73. The ~~method~~use of claim 72, wherein the wound is not healing at an expected rate.

74. The ~~method~~use of claim 72, wherein the wound is delayed, difficult to heal, or chronic.

75. The ~~method~~use of claim 72, wherein the wound is characterized at least in part by increased expression of OGT.

76. The ~~method~~use of any one of claims 44 and 46-53, wherein the cell includes insulin-resistant receptors.

77. The ~~method~~use of claim 76, wherein the cell is in a subject.

78. The ~~method~~use of any one of claims 45-75 and 77, wherein the subject is not a diabetic

79. The ~~method~~use of any one of claims 45-75 and 77, wherein the subject is diabetic.

80. The ~~method~~use of claim 79, wherein the subject has type 1 diabetes mellitus.

81. The ~~method~~use of claim 79, wherein the subject has type 2 diabetes mellitus.

82. The ~~method~~use of any one of claims 45-75 and 77, wherein the subject has higher than normal blood glucose levels.

83. The ~~method~~use of any one of claims 45-75 and 77, the subject has insulin-resistant receptors.

84. The ~~method~~use of any one of claims 45-83, further comprising the step of administering a second wound healing agent.

85. The ~~method~~use of any one of claims 45-83, further comprising the step of administering a second anti-OGT agent.